isqfdq1q

Property	Value
?:abstract	OBJECTIVE: To perform an updated review of the literature on the neurological manifestations of COVID-19-infected patients METHODS: A PRISMA-guideline-based systematic review was conducted on PubMed, EMBASE, and SCOPUS. Series reporting neurological manifestations of COVID-19 patients were studied. RESULTS: 39 studies and 68,361 laboratory-confirmed COVID-19 patients were included. Up to 21.3% of COVID-19 patients presented neurological symptoms. Headache (5.4%), skeletal muscle injury (5.1%), psychiatric disorders (4.6%), impaired consciousness (2.8%), gustatory/olfactory dysfunction (2.3%), acute cerebrovascular events (1.4%), and dizziness (1.3%), were the most frequently reported neurological manifestations. Ischemic stroke occurred among 1.3% of COVID-19 patients. Other less common neurological manifestations were cranial nerve impairment (0.6%), nerve root and plexus disorders (0.4%), epilepsy (0.7%), and hemorrhagic stroke (0.15%). Impaired consciousness and acute cerebrovascular events were reported in 14% and 4% of patients with a severe disease, respectively, and they were significantly higher compared to non-severe patients (p < 0.05). Individual patient data from 129 COVID-19 patients with acute ischemic stroke (AIS) were extracted: mean age was 64.4 (SD ± 6.2), 78.5% had anterior circulation occlusions, the mean NIHSS was 15 (SD ± 7), and the intra-hospital mortality rate was 22.8%. Admission to the intensive care unit (ICU) was required among 63% of patients. CONCLUSION: This updated review of literature, shows that headache, skeletal muscle injury, psychiatric disorders, impaired consciousness, and gustatory/olfactory dysfunction were the most common neurological symptoms of COVID-19 patients. Impaired consciousness and acute cerebrovascular events were significantly higher among patients with a severe infection. AIS patients required ICU admission in 63% of cases, while intra-hospital mortality rate was close to 23%. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00415-020-10285-9) contains supplementary material, which is available to authorized users.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/isqfdq1q_hasAnnotation_C0004936> <https://research.tib.eu/covid-19/entity/isqfdq1q_hasAnnotation_C0012833> <https://research.tib.eu/covid-19/entity/isqfdq1q_hasAnnotation_C0018681> <https://research.tib.eu/covid-19/entity/isqfdq1q_hasAnnotation_C0235031> <https://research.tib.eu/covid-19/entity/isqfdq1q_hasAnnotation_C0597457> <https://research.tib.eu/covid-19/entity/isqfdq1q_hasAnnotation_C1335589> <https://research.tib.eu/covid-19/entity/isqfdq1q_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Cagnazzo%2C_Federico%3B_Arquizan%2C_Caroline%3B_Derraz%2C_Imad%3B_Dargazanli%2C_Cyril%3B_Lefevre%2C_Pierre-Henri%3B_Riquelme%2C_Carlos%3B_Gaillard%2C_Nicolas%3B_Mourand%2C_Isabelle%3B_Gascou%2C_Gregory%3B_Bonafe%2C_Alain%3B_Costalat%2C_Vincent>
?:doi	10.1007/s00415-020-10285-9
?:doi	<https://research.tib.eu/covid-19/entity/10.1007/s00415-020-10285-9>
?:journal	J_Neurol
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/07cb422ef9ef5b4ea053b2c306a08fb90829b2af.json
?:pmc_json_files	document_parses/pmc_json/PMC7597753.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7597753>
?:pmid	<https://research.tib.eu/covid-19/entity/33125542.0>
?:pmid	33125542.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/07cb422ef9ef5b4ea053b2c306a08fb90829b2af>
?:source	Medline; PMC
?:title	Neurological manifestations of patients infected with the SARS-CoV-2: a systematic review of the literature
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-10-30

Property

Value

?:abstract

OBJECTIVE: To perform an updated review of the literature on the neurological manifestations of COVID-19-infected patients METHODS: A PRISMA-guideline-based systematic review was conducted on PubMed, EMBASE, and SCOPUS. Series reporting neurological manifestations of COVID-19 patients were studied. RESULTS: 39 studies and 68,361 laboratory-confirmed COVID-19 patients were included. Up to 21.3% of COVID-19 patients presented neurological symptoms. Headache (5.4%), skeletal muscle injury (5.1%), psychiatric disorders (4.6%), impaired consciousness (2.8%), gustatory/olfactory dysfunction (2.3%), acute cerebrovascular events (1.4%), and dizziness (1.3%), were the most frequently reported neurological manifestations. Ischemic stroke occurred among 1.3% of COVID-19 patients. Other less common neurological manifestations were cranial nerve impairment (0.6%), nerve root and plexus disorders (0.4%), epilepsy (0.7%), and hemorrhagic stroke (0.15%). Impaired consciousness and acute cerebrovascular events were reported in 14% and 4% of patients with a severe disease, respectively, and they were significantly higher compared to non-severe patients (p < 0.05). Individual patient data from 129 COVID-19 patients with acute ischemic stroke (AIS) were extracted: mean age was 64.4 (SD ± 6.2), 78.5% had anterior circulation occlusions, the mean NIHSS was 15 (SD ± 7), and the intra-hospital mortality rate was 22.8%. Admission to the intensive care unit (ICU) was required among 63% of patients. CONCLUSION: This updated review of literature, shows that headache, skeletal muscle injury, psychiatric disorders, impaired consciousness, and gustatory/olfactory dysfunction were the most common neurological symptoms of COVID-19 patients. Impaired consciousness and acute cerebrovascular events were significantly higher among patients with a severe infection. AIS patients required ICU admission in 63% of cases, while intra-hospital mortality rate was close to 23%. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00415-020-10285-9) contains supplementary material, which is available to authorized users.

is ?:annotates of